HSC Exam Practice

Sample response. Biopiracy is the commercial use of biological resources or traditional knowledge by a company, research institution, or government agency without the free prior informed consent of the knowledge-holding community and without sharing any commercial benefits that result.

Marking notes. 1 mark for identifying appropriation without consent; 1 mark for identifying no benefit sharing (or "no return to the community"). Both elements required for full marks — consent alone or benefit sharing alone is worth only 1 mark.

Sample response. Both bioprospecting and biopiracy involve searching for commercially useful biological compounds in nature. Bioprospecting is ethical because it obtains free prior informed consent from the relevant community or country before research begins and negotiates a benefit-sharing agreement — so the community that holds the knowledge participates in the commercial outcome. Biopiracy uses the same biological knowledge without obtaining consent and without sharing any benefits — the community contributes to the research outcome but receives nothing in return. The biological knowledge used may be identical; the ethical and legal distinction lies entirely in the process of engagement with the knowledge-holding community.

Marking notes. 1 mark for defining the shared feature (both involve use of biological knowledge/compounds for commercial purposes); 1 mark for bioprospecting distinction (FPIC + benefit sharing present); 1 mark for biopiracy distinction (no consent, no benefit sharing). A response that only defines biopiracy without comparing to bioprospecting scores a maximum of 2.

Sample response. Acceptable named examples with correctly matched properties include: Tea tree (Melaleuca alternifolia) — broad-spectrum antimicrobial and antifungal activity; Kakadu plum (Terminalia ferdinandiana) — highest known Vitamin C content of any food (3000 mg/100 g), antimicrobial and antioxidant properties; Eremophila (Eremophila spp.) — antimicrobial serrulatane compounds, active research in MRSA treatment; Eucalyptus (Eucalyptus spp.) — cineole compound, documented anti-inflammatory activity; Lemon myrtle (Backhousia citriodora) — high citral content, documented as stronger antimicrobial than tea tree against some bacterial strains; Smoke bush (Conospermum spp.) — conospermines with in vitro activity against HIV.

Marking notes. 1 mark per correctly named plant (common or scientific name accepted) paired with a specifically described biological property. 2 marks maximum. A correct plant name without a specific property, or a property without a plant name, scores 0 for that entry.

Sample response. Standard patent law grants patents only on inventions that are novel — that is, not already present in the existing knowledge base (prior art) that patent examiners consult when assessing an application. Prior art is defined by what can be found in searchable, indexed databases: patent records, scientific journals, and published books. Traditional knowledge held and transmitted orally by Indigenous communities is typically not documented in any of these indexed sources. A patent examiner therefore cannot find it when searching for prior art. As a result, a compound that has been known and used by a community for thousands of years can appear novel from the patent examiner's perspective — and a patent can be granted, legally excluding the original knowledge-holders from commercialising the resource, even though their knowledge existed long before the patent application.

Marking notes. 1 mark for correctly defining prior art (existing knowledge that prevents a patent for lack of novelty); 1 mark for identifying that oral traditional knowledge is not documented in indexed databases and therefore is not discoverable as prior art by patent examiners; 1 mark for explaining the consequence — the compound appears novel, the patent is granted, and the community has no legal mechanism to challenge it.

Sample response. The Nagoya Protocol requires three things. First, free prior informed consent (FPIC) must be obtained from the relevant community or country before any access to genetic resources or traditional knowledge begins — the consent must be genuinely free, obtained prior to any research, and based on full information about what is proposed. Second, mutually agreed terms must be negotiated: the conditions of access, intellectual property arrangements, and benefit-sharing terms must be agreed between the researcher and the community before access begins, not after commercial outcomes are established. Third, equitable benefit sharing: any commercial benefits arising from use of the resources or knowledge must be shared with the providers in accordance with the agreed terms.

Marking notes. 1 mark per requirement correctly named and briefly described — all three required (FPIC; mutually agreed terms; equitable benefit sharing). A response that names three requirements without any description scores 1 mark total. A response that describes FPIC and benefit sharing but omits mutually agreed terms scores 2 marks.

Sample response. The Noongar community had no effective legal recourse for several interconnected reasons. First, their knowledge of smoke bush's medicinal properties was oral — held within community practice and transmitted across generations through cultural frameworks, not documented in any written or indexed form that patent offices recognise. This meant their knowledge could not function as prior art: a patent examiner searching databases for existing knowledge of the plant's anti-HIV compounds would find nothing, so the compounds appeared novel and the patent met the legal requirement for novelty. Second, at the time the NCI obtained collection permits from the Western Australian government, those permits did not require any consultation with, or consent from, Indigenous communities — the legal framework for collection simply did not include community engagement requirements. The collection was therefore entirely lawful under the law at the time. Third, the community had no formal agreement, contract, or benefit-sharing arrangement with the NCI — without a prior legal relationship there was no contract to enforce and no remedy in contract law. The Nagoya Protocol (2010, in force 2014) and Australia's ratification (2022) came decades after the incident, and the Protocol is not retrospective.

Marking notes. 1 mark for the prior art gap (oral knowledge not indexed, therefore not discoverable as prior art, patent appears valid); 1 mark for the collection permit system (WA collection permits did not require Indigenous community consultation); 1 mark for the absence of a prior legal relationship (no contract, no benefit-sharing agreement = no contractual remedy); 1 mark for the retrospectivity limitation (Nagoya Protocol and domestic legislation came later and do not apply retrospectively to this case). Three well-developed points may also earn 4 marks if they demonstrate comprehensive understanding — do not require all four exactly as worded.

Sample response (a) — 2 marks. Lemon myrtle oil (Backhousia citriodora) shows the strongest antimicrobial activity overall, with the lowest MIC values across all three bacterial species (0.12 mg/mL against S. aureus, 0.25 mg/mL against E. coli, and 0.25 mg/mL against MRSA). Because lower MIC values indicate stronger inhibition, lemon myrtle oil requires the lowest concentration to completely inhibit growth — making it the most potent extract in the dataset. [1 mark for identifying lemon myrtle; 1 mark for justifying with specific data values]

Sample response (b) — 3 marks. Eremophila extract shows a MIC of 0.40 mg/mL against S. aureus and 0.20 mg/mL against MRSA. The lower MIC against MRSA (0.20) than against the standard S. aureus strain (0.40) indicates that Eremophila extract is actually more potent against the antibiotic-resistant MRSA strain than against the non-resistant strain [1]. This is of particular clinical interest because MRSA (methicillin-resistant Staphylococcus aureus) is resistant to standard beta-lactam antibiotics including methicillin and many penicillin derivatives, making infections difficult and expensive to treat [1]. A plant extract that shows stronger activity against the resistant form than the non-resistant form is a promising research lead for new anti-MRSA therapeutic agents [1].

Sample response (c) — 2 marks. The ethical concern is that the traditional knowledge of Aboriginal and Torres Strait Islander communities — who used lemon myrtle for medicinal purposes — directed or at least contextualises the research that identified the plant as worth investigating pharmaceutically. Beginning research on citral without contacting any Indigenous communities means there is no free prior informed consent [1], and no benefit-sharing arrangement will be in place when commercial outcomes are developed — meaning any community whose knowledge contributed to identifying the plant's medicinal relevance will receive no return from that contribution. This meets the definition of biopiracy: commercial use of knowledge or resources without community consent or benefit sharing [1].

Sample response. The Nagoya Protocol on Access and Benefit-Sharing represents the most significant international legal advance in protecting Indigenous communities from biopiracy, but its protections are meaningful without being complete. A balanced evaluation requires examining both its genuine strengths and its well-documented limitations.

The Protocol's strengths lie in the procedural requirements it establishes. For access to genetic resources and traditional knowledge, it requires three things: free prior informed consent from the relevant community or country before research begins; mutually agreed terms negotiated before any use; and equitable benefit sharing of any commercial outcomes. These requirements directly address the structural failures exposed by cases such as the smoke bush patent. In the early 1990s, the US National Cancer Institute collected Conospermum spp. from Western Australia — a plant used by Noongar people for respiratory conditions and healing — identified anti-HIV compounds (conospermines), and filed a patent without notifying the Noongar community, obtaining their consent, or offering any benefit-sharing arrangement. The community had no legal recourse because their oral knowledge was not indexed in patent databases and could not constitute prior art under patent law. Had the Nagoya Protocol's requirements been in force, the NCI would have been legally obliged to obtain Noongar consent before collection and to negotiate benefit-sharing terms before pursuing commercial development. This is a genuine and important advance: the Protocol shifts the legal burden onto the researcher to engage communities first, rather than leaving communities to challenge patent filings after the fact.

However, the Protocol has at least four significant limitations that prevent it from offering comprehensive protection. First, it is explicitly not retrospective: it applies only to resources accessed after it entered into force in October 2014. Historical cases of biopiracy — including the smoke bush patent — receive no remedy under the Protocol. The communities affected by pre-2014 appropriations have no avenue to claim benefit sharing for those cases regardless of how clear the biopiracy was. Second, implementation requires domestic legislation in each signatory country, and the strength and detail of that legislation varies considerably. Australia ratified the Protocol in 2022 but domestic access and benefit-sharing legislation was still developing — without enforceable domestic law, the Protocol's requirements may not be actionable in Australian courts even for post-2022 cases. Third, the fundamental problem the smoke bush case exposed — that oral traditional knowledge is not recognised as prior art in patent systems — has not been resolved by the Nagoya Protocol. The Protocol requires consent before access, but it does not reform the patent system's treatment of oral knowledge. A company could potentially still obtain a patent on a traditional compound if it accessed the plant through means not covered by the Protocol, and the community's oral knowledge would still not constitute prior art. Fourth, enforcement mechanisms are limited: the Protocol relies on domestic law in the country of the researcher, and verification systems for compliance are not uniformly developed.

Overall, the Nagoya Protocol adequately protects traditional knowledge in the sense that it establishes the right framework — consent, agreed terms, benefit sharing — and represents an international consensus that traditional knowledge has identifiable owners whose rights must be respected. For access that occurs in signatory countries with strong domestic ABS legislation, after 2014, to communities aware of their rights under the Protocol, the protection is meaningful. But for historical cases, for communities in countries with weak domestic implementation, and for situations where oral knowledge remains undocumented and unprotectable as prior art, significant gaps remain. The Protocol is necessary but not sufficient: ongoing advocacy for reformed patent systems, stronger domestic legislation, and community knowledge-documentation programs is still required to close the gaps the smoke bush case first made visible.

Marking notes.

• 1 mark — Correctly identifies and describes at least two of the three core Nagoya Protocol requirements (FPIC; mutually agreed terms; equitable benefit sharing) and links them to how they would prevent biopiracy.
• 1 mark — Uses the smoke bush / Noongar case (or another named Australian example) with specific factual detail to illustrate the type of biopiracy the Protocol is designed to prevent.
• 1 mark — Identifies the retrospectivity limitation correctly: the Protocol does not apply to pre-2014 cases; historical biopiracy receives no remedy.
• 1 mark — Identifies the domestic legislation limitation: effectiveness depends on each country enacting and enforcing access and benefit-sharing laws; variable implementation undermines uniform protection.
• 1 mark — Identifies at least one other specific limitation (prior art problem not resolved; enforcement mechanisms limited; oral knowledge still not protected in patent systems; not all countries have ratified).
• 1 mark — Reaches a nuanced overall evaluation — not "the Protocol solves biopiracy" nor "the Protocol is useless" — that accurately characterises the extent of protection (meaningful but incomplete; depends on domestic implementation; historical gaps remain).
• 1 mark (quality) — Response uses precise lesson terminology throughout: FPIC, mutually agreed terms, benefit sharing, prior art, biopiracy, traditional knowledge, Nagoya Protocol, and engages with Australian context.
• 1 mark (quality) — Response is coherently structured and sustained: strengths and limitations are developed with reasoning rather than listed, and the overall evaluation integrates the analysis rather than just repeating earlier points.